

# Expressed wishes and incidence of euthanasia in advanced lung cancer patients

Koen Pardon\*, Reginald Deschepper\*, Robert Vander Stichele\*, Jan L. Bernheim\*, Freddy Mortier\*, Denis Schallier\*, Paul Germonpré§, Daniella Galdermansf, Willem Van Kerckhoven\*\* and Luc Deliens\*, on behalf of the EOLIC-consortium

ABSTRACT: This study explores expressed wishes and requests for euthanasia (i.e. administration of lethal drugs at the explicit request of the patient), and incidence of end-of-life decisions with possible life-shortening effects (ELDs) in advanced lung cancer patients in Flanders, Belgium.

We performed a prospective, longitudinal, observational study of a consecutive sample of advanced lung cancer patients and selected those who died within 18 months of diagnosis. Immediately after death, the pulmonologist/oncologist and general practitioner (GP) of the patient filled in a questionnaire. Information was available for 105 out of 115 deaths.

According to the specialist or GP, one in five patients had expressed a wish for euthanasia; and three in four of these had made an explicit and repeated request. One in two of these received euthanasia. Of the patients who had expressed a wish for euthanasia but had not made an explicit and repeated request, none received euthanasia. Patients with a palliative treatment goal at inclusion were more likely to receive euthanasia. Death was preceded by an ELD in 62.9% of patients.

To conclude, advanced lung cancer patients who expressed a euthanasia wish were often determined. Euthanasia was performed significantly more among patients whose treatment goal after diagnosis was exclusively palliative.

KEYWORDS: End-of-life decisions, nonsmall cell lung cancer, palliative care

Il over the world, physicians receive requests for euthanasia from seriously ill patients and sometimes accede to these requests [1–5]. However, euthanasia is only legally permitted, under well-defined conditions, in three European countries: Belgium, the Netherlands and Luxembourg [6–8]. The principal conditions that are laid down in the euthanasia law in these countries are that 1) the patient must be in a condition of constant and unbearable physical and/or mental suffering caused by illness or accident, with no possibility of improvement and 2) the request must be made voluntarily and be well considered and repeated.

Several nationwide population studies in Flanders (Belgium) and the Netherlands have determined the incidence of euthanasia and other end-of-life decisions with possible or certain life-shortening effects (ELDs) [2, 9, 10]. These studies have never

been disease specific, nor have they qualified more in depth the process leading towards euthanasia. This study focuses on advanced lung cancer patients and studies in depth the process leading to euthanasia, the most controversial of ELDs. Advanced lung cancer is one of the most deadly diseases, with a high symptom burden, usually requiring a high level of care and therapy [11, 12].

In Flanders and the Netherlands, it has been shown that the practice of euthanasia is relatively rare when considering all deaths (1.9% in Flanders in 2007 and 1.7% in the Netherlands in 2005) and more prevalent in deaths caused by cancer (5.6% in Flanders and 5.1% in the Netherlands) [2, 10]. Little is known, however, about the processes that lead to euthanasia, more specifically about the number of patients who express a wish for euthanasia to the physician, whether this is an explicit and repeated request and whether it leads to euthanasia.

AFFILIATIONS

\*End-of-Life Care Research group, Ghent University and Vrije Universiteit Brussel, \*Dept of Medical Oncology, University Hospital of Brussels,

Brussels,
#Heymans Institute for
Pharmacology, Ghent University,
\*Bioethics Institute Ghent, Ghent
University, Ghent,
\*Dept of Pulmonary Medicine,
University Hospital of Antwerp,
Edegem,

<sup>f</sup>Dept of Pulmonary Medicine, ZNA Middelheim Hospital, Antwerp, \*\*Dept of Pulmonary Medicine,

\*\*Dept of Pulmonary Medicine, Hospital Sint-Augustinus, Wilrijk, Belgium.

##Dept of Public and Occupational Health, EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, the Netherlands.

¶¶EOLIC consortium members and their affiliations can be found in the Acknowledgements section.

CORRESPONDENCE
K. Pardon
End-of-life Care Research group
Ghent University and Vrije
Universiteit Brussel
Laarbeeklaan 103
1090 Brussels
Belgium

E-mail: koen.pardon@vub.ac.be

Received: Oct 19 2011 Accepted after revision: Jan 17 2012

Jan 17 2012 First published online: April 20 2012

European Respiratory Journal Print ISSN 0903-1936 Online ISSN 1399-3003

For editorial comments see page 804.

Therefore, this study aims to examine the relationship between euthanasia wishes, euthanasia requests and euthanasia practices in a sample of advanced lung cancer patients in Flanders and the incidence of euthanasia and other ELDs among these patients. It is interesting to study ELDs in Flanders: it is one of the first European countries that accepted a law on euthanasia and it is a country in which great importance is attached to patient autonomy in medical decision-making, *e.g.* through the law on patient rights of 2002 [13]. International comparative research has shown that such cultural factors as patient autonomy and legal status strongly determine the incidence of certain ELDs such as euthanasia [3, 14].

The research questions were: 1) How many patients with advanced lung cancer wish and request euthanasia, and how often is their request implemented? 2) What characterises the patients who choose euthanasia? 3) What is the incidence of euthanasia and other ELDs among patients with advanced lung cancer?

# **METHODS**

For the purpose of analysis in this paper, we selected patients who were included in a previous longitudinal interview study [15]. Patients conformed to the following inclusion criteria: a recent initial diagnosis of nonsmall cell lung cancer (NSCLC) stage IIIb or IV, 18 yrs or older, Dutch speaking and physically and psychologically able to participate in the study. The patients were recruited consecutively during one year by pulmonologists and oncologists in 13 hospitals in Flanders. We asked the pulmonologist or oncologist and the general practitioner (GP) of the patient to fill in an after-death questionnaire for those patients who died within 18 months of inclusion in the study.

# Measurements

Inclusion form

At inclusion of the patient in the longitudinal interview study, socio-demographic and clinical characteristics were collected including age, sex, educational level, whether the patient lived with a partner, intention of treatment, comorbidity (Charlson's Comorbidity Index [16, 17]), whether the patient had a GP and how frequent the contact with the GP was (see online supplementary material).

# After death questionnaire

In the after death questionnaire (see online supplementary material) to be filled in by the treating pulmonologist or oncologist and the GP, the physicians were asked whether the patient had ever expressed a wish for them to administer drugs with the explicit intention of hastening death (we deliberately used a descriptive definition of euthanasia). Then the physician was asked whether explicit and repeated requests had been made. Finally, we measured the occurrence of ELDs, including euthanasia, and the practice of continuous deep sedation until death. ELDs studied were: withholding or withdrawing potentially life-prolonging treatment, intensified alleviation of symptoms and physician assisted death (euthanasia, physician assisted suicide and ending of life without the patient's explicit request). For the practice of continuous deep sedation until death, we asked whether the patient had been deeply sedated until death with or without the artificial administration of food or fluid. The wording of the questions and classification of practices were identical to previous nationwide incidence studies [1, 2].

In a separate section of the questionnaire, characteristics of the patient and of death were measured: performance status in the last week before death (ECOG, Eastern Cooperative Oncology Group [18]), whether the patient had died suddenly and unexpectedly, place of death (home, hospital, nursing home or hospice), and quality of death according to the physician (10-point Likert-scale from bad to good).

# Ethical aspects

All patients were asked for informed consent to enter the study, and this was renewed at each interview. The protocol was approved by the Ethics Committees of all participating hospitals. A list of the participating hospitals can be found in the Acknowledgements section.

# Statistical analysis

To compare the characteristics of those patients who had expressed a wish for euthanasia with those who had not and to compare the characteristics of those who died after euthanasia and those who did not, the Mann–Whitney U or Fisher's exact test was used; significance was set at p < 0.05.

### **RESULTS**

Pulmonologists and oncologists of the participating hospitals screened 291 patients with a recent initial diagnosis of NSCLC, stage IIIb or IV. 95 patients did not meet the inclusion criteria: 45 patients were physically unable to participate, 34 were psychologically unable to participate, 12 were non-Dutch speaking and four had a combination of the former reasons. With regard to exclusion due to psychological problems: the following problems were mentioned: low IQ (eight patients), psychiatric disorder (12 patients), high anxiety (seven patients), personality disorder (four patients) and total denial of their medical condition (three patients). Of the 196 patients who met the inclusion criteria, 152 were included in the study: 36 patients refused participation and eight were excluded by the specialist (e.g. because they participated in another study). The included patients did not significantly differ with regard to age and sex from the patients who refused participation or were excluded even though they fitted the inclusion criteria, but they had a higher performance status (p=0.006) and mean estimated life expectancy (10.3 versus 8.3 months since diagnosis, p=0.014). Of the 152 patients who agreed to participate, 115 died within 18 months from diagnosis. Finally, for 105 patients, a valid after death questionnaire was returned from the treating physician or physicians. The response rate of specialists was 91.3% and of GPs 54.8% (fig. 1).


# Characteristics of the studied patients

The characteristics of the studied patients are shown in table 1.

The mean  $\pm$  SD age of the studied patients at inclusion was  $64.6\pm10.6$  yrs; 87 (82.9%) patients were male and 76 (74.5%) had a partner. The treatment patients received at inclusion had a life-prolonging intent in three-quarters and a palliative intent in one-quarter. Most received chemotherapy.

In the last week before death 70 (72.2%) patients were completely disabled according to the ECOG performance-scale. 73 (70.9%) patients died in the hospital where they were receiving treatment, 15 (14.6%) died under GP care, and 15 (14.6%) died elsewhere *e.g.* in a hospice.

K. PARDON ET AL. LUNG CANCER



**FIGURE 1.** Selection of nonsmall cell lung cancer (NSCLC) IIIb–IV patients for study. GP: general practitioner.

# Euthanasia: expressed wish, request and implementation of request

Euthanasia in advanced lung cancer patients, wishes, request and implementations are shown in figure 2.

According to the specialist and/or GP, 21 (20.0%) out of of 105 advanced lung cancer patients who died within 18 months of diagnosis had expressed a wish for euthanasia. Specialist and GP did not always agree on the existence of a wish. Of the 13 patients with a euthanasia wish for which both specialist and GP had filled in the questionnaire, six patients were reported to have a wish by both physicians, and seven only by one physician (four specialists and three GPs reported a wish expressed, while their colleague reported that no such wish had been expressed).

Of the 21 patients who had expressed a wish for euthanasia, 15 (14.3% of all patients) had explicitly and repeatedly asked the physician (specialist and/or GP) for euthanasia. Specialist and GP also did not always agree on the existence of an explicit and repeated request. Of the six cases for which both specialist and GP had reported the expression of a euthanasia wish, four patients were reported to have made an explicit and repeated request by both physicians, and two by only one, while the other did not report the making of a request.

Of the 15 patients finally who had explicitly and repeatedly requested euthanasia, 8 (7.6% of all patients) received euthanasia (fig. 2). None of the patients who had expressed a wish but not an explicit and repeated request (5.7% of all patients) received euthanasia.

In seven patients euthanasia was not performed despite an explicit and repeated request. Possible reasons for not performing euthanasia could be found in the comments of the physicians. Comments were given in three of the seven cases, each time by the GP (not shown in fig. 2). In one case the patient died before euthanasia could be performed; in another case the patient died in a palliative care unit where he had not repeated his request. In a third case, the patient had asked for euthanasia when suffering became intolerable, but this did not happen according to the physician. In four of seven cases no explanation for not performing euthanasia was given, but we observed that these four patients died in a setting other than that of the reporting physician. In two of these four cases the GP had reported a wish and an explicit and repeated request for euthanasia while the specialist had not, and the patient died in the setting of the specialist. In one case both physicians (specialist and GP) had reported an explicit and repeated request but the patient died in yet another setting. In the last case, only the GP had filled in the questionnaire regarding the death of the patient, but the patient died in a setting other than that of the GP.

We also compared the socio-demographic and clinical characteristics of the seven patients who did not receive euthanasia despite a request with the eight who did: the seven patients lived significantly less long (median of 3 *versus* 10 months, p=0.027) and died significantly less often in the hospital (p=0.041).

# Characteristics associated with a wish for euthanasia, an explicit and repeated request for euthanasia and implementation of euthanasia

Expressing a wish, making an explicit and repeated request and receiving euthanasia were not related to age, sex, education and having a partner, or to clinical characteristics such as the frequency of contact with the GP or the treatment hospital (university *versus* general hospital) (table 1). There were, however, significant positive associations with a palliative treatment goal at inclusion and with not being treated with chemotherapy at inclusion.

There was a significant positive association between the expression of a euthanasia wish or euthanasia and the length of time after diagnosis. Another association concerned the one between receiving euthanasia and a high comorbidity score. There was a positive trend (but not significant) in the association between dying at home (under the care of the GP) and having expressed a wish for euthanasia.

# End-of-life decisions other than euthanasia, including continuous deep sedation until death

End of life decisions other than euthanasia are shown in table 2.

Sudden death struck 11 (10.5%) patients; 28 (26.6%) died nonsuddenly without a preceding ELD and 66 (62.9%) died nonsuddenly with at least one ELD preceding death. Euthanasia was performed in eight patients or 7.6% of all studied patients. In 15 (14.3%) patients, the ELD consisted of withholding or withdrawing potential life-prolonging treatment (without intent



EUROPEAN RESPIRATORY JOURNAL VOLUME 40 NUMBER 4 951

Outmospheristical in intuitisation of the patient in the matrix places at inclusion of the patient in the matrix placement and patient)         23         15         15         10         646-29         670-102         640-89         0.001         646-29         646-29         646-29         666-29         646-29		All patients	Patients whee	Patients who had euthanasia wish, compared with those who did not	sia wish, did not	Patients who request comp	Patients who had an explicit and repeated request compared with those who did not	nd repeated who did not	Patients w compared	Patients who received euthanasia, compared with those who did not	anasia, did not
64 6 ± 99 (53.2 ± 10 6 (64.9 ± 97) (57.2 (53.0 ± 10.00) (13 (14.9)) (26.11 10.00) (13 (14.9)) (26.11 10.00) (13 (14.9)) (26.11 10.00) (13 (14.9)) (26.11 10.00) (13 (14.9)) (26.11 10.00) (13 (14.9)) (26.11 10.00) (26.12 10.00)			Wish	No wish	p-value#	Request	No request	p-value#	Euthanasia	No euthanasia	p-value#
1   105   115	Characteristics at inclusion of the patient in the study (source: specialist and patient)										
e printing and a problem of the prob	Subjects n		21	84		15	06		∞	26	
Part	Age yrs	$64.6 \pm 9.9$	$63.2 \pm 10.6$	64.9 ± 9.7	0.572	$63.0 \pm 10.2$	(6.8 (9.9)	0.601	64.5±9.8	64.6 ± 9.9	926.0
87 (82.9)         13 (82.7)         15 (83.3)         1000         13 (14.9)         74 (85.1)         1000         13 (14.9)         74 (85.1)         1000         13 (14.9)         74 (85.1)         1000         11 (14.5)         10 (83.9)         1000         11 (14.5)         10 (83.9)         1000         11 (14.5)         11 (14.5)         66 (36.5)         1000         17 (14.4)         11 (14.5)         66 (36.5)         1000         17 (14.4)         11 (14.5)         66 (36.5)         1000         17 (14.4)         11 (14.5)         66 (36.5)         10 (37.5)         11 (14.5)         11 (14.5)         66 (36.5)         10 (37.5)         11 (14.5)         11 (14.5)         10 (36.5)         11 (14.5)	Sex										
16 (7.1) 3 (6.7) 16 (8.3.3) 2 (1.11) 16 (8.9.3) 16 (8.9.3) 16 (8.9.4) 17 (84.4) 17 (84.4) 18 (8.9.2) 17 (84.4) 18 (8.9.2) 18 (6.7.2) 18 (8.9.2)	Male	87 (82.9)	18 (20.7)	(69 (79.3)	1.000	13 (14.9)	74 (85.1)	1.000	7 (8.0)	80 (92.0)	1.000
76 (74.5)         16 (21.1)         60 (78.9)         0.775         11 (14.5)         65 (85.5)         1000         6 (7.9)         77 (79.2)           26 (25.5)         4 (15.4)         22 (84.6)         2 (11.1)         10 (88.9)         0.366         1 (15.6)         1 (17.44)         24 (92.9)           18 (17.5)         4 (22.2)         14 (77.8)         0.675         2 (11.1)         10 (88.9)         0.388         1 (15.6)         1 (17.44)         24 (81.9)           20 (19.4)         5 (25.0)         15 (75.0)         4 (80.0)         0.3931         1 (12.0)         4 (80.0)         0.387         1 (20.0)         1 (17.44)         1 (84.6)         1 (17.44)<	Female	18 (17.1)	3 (16.7)	15 (83.3)		2 (11.1)	16 (88.9)		1 (5.6)	17 (94.4)	
Red (25.5)         16 (21.1)         60 (78.9)         0.775         11 (14.5)         66 (86.5)         1.000         6 (7.9)         70 (82.1)           18 (17.5)         4 (15.4)         2 (8.6)         3 (11.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         2 (18.5)         3 (18.1)         3 (18.5)         2 (18.5)         2 (18.5)         3 (18.1)         3 (18.5)         3 (18.1)         3	Having a partner										
See (25.5)         4 (15.4)         22 (84.6)         3 (11.5)         23 (84.5)         2 (13.7)         24 (82.3)         2 (13.4)         2 (13.4)         2 (13.4)         2 (13.4)         2 (15.6)         2 (13.4)         2 (13.4)         2 (13.4)         2 (13.4)         2 (13.4)         2 (13.4)         2 (13.4)         2 (13.4)         2 (13.4)         3 (13.4)	Yes	76 (74.5)	16 (21.1)		0.775	11 (14.5)	65 (85.5)	1.000	(6.7.9)	70 (92.1)	1.000
18 (175)   4 (222)   14 (778)   0 6675   2 (11.1)   16 (883)   0 3868   1 (5.6)   17 (94.4)     28 (27.2)   6 (21.4)   2 (78.6)   3 (8.1)   3 (8.1)   3 (8.1)   3 (8.1)   3 (8.1)     28 (27.2)   6 (21.4)   2 (78.6)   3 (8.1)   3 (8.1)   3 (8.1)   3 (8.2)     29 (27.2)   6 (21.4)   2 (78.6)   3 (8.2)   3 (8.2)   3 (8.2)   3 (8.2)     20 (18.4)   5 (25.0)   4 (80.0)   0 9371   1 (25.0)   4 (80.0)   3 (8.2)   3 (8.2)     20 (18.4)   2 (15.4)   1 (84.6)   2 (15.4)   1 (184.6)   3 (15.4)   3 (18.6)     30 (21.4)   2 (15.4)   1 (184.6)   3 (15.4)   3 (18.6)   3 (18.6)     30 (21.4)   3 (12.1)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)   3 (18.6)     30 (21.4)   3 (18.6)   3 (	No	26 (25.5)	4 (15.4)			3 (11.5)	23 (88.5)		2 (7.7)	24 (92.3)	
18 (17.5) 4 (22.2) 14 (77.8) 0 675 2 (11.1) 16 (88.9) 0.368 1 (5.6) 17 (94.4	Education										
37 (35.9)         5 (13.5)         22 (85.7)         26 (13.1)         22 (73.1)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         24 (91.9)         25 (25.0)         15 (75.0)         4 (90.0)         25 (25.0)         15 (75.0)         4 (90.0)         25 (25.0)         15 (75.0)         4 (90.0)         25 (25.0)         11 (24.4)         24 (41.9)         24 (41.9)         11 (24.4)         24 (41.9)         24	Primary school	18 (17.5)	4 (22.2)	14 (77.8)	0.675	2 (11.1)	16 (88.9)	0.368	1 (5.6)	17 (94.4)	1.000
28 (27.2) 6 (21.4) 22 (78.6) 1 (75.0) 2 (75.0) 1 (75.0) 2 (75.0) 1 (75.0) 2 (75.0) 2 (77.1) 26 (92.9) 2 (19.4) 2 (19.6) 1 (15.0) 2 (19.6) 1 (15.0) 2 (15.0) 1 (12.0) 2 (15.0)	Lower secondary	37 (35.9)	5 (13.5)	32 (86.5)		3 (8.1)	34 (91.9)		3 (8.1)	34 (91.9)	
week         5 (48)         1 (75.0)         4 (80.0)         0.931         1 (75.0)         4 (80.0)         15 (75.0)         4 (80.0)         15 (75.0)         4 (80.0)         15 (75.0)         4 (80.0)         15 (75.0)         4 (80.0)         16 (75.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)         4 (80.0)         1 (20.0)         4 (80.0) <th< td=""><td>Higher secondary</td><td>28 (27.2)</td><td>6 (21.4)</td><td>22 (78.6)</td><td></td><td>4 (14.3)</td><td>24 (85.7)</td><td></td><td>2 (7.1)</td><td>26 (92.9)</td><td></td></th<>	Higher secondary	28 (27.2)	6 (21.4)	22 (78.6)		4 (14.3)	24 (85.7)		2 (7.1)	26 (92.9)	
week         5 (4.8)         1 (20.0)         4 (80.0)         0.9331         1 (20.0)         4 (80.0)         0.9337         1 (20.0)         4 (80.0)           9 (7.6)         2 (25.0)         6 (75.0)         1 (11.5.5)         7 (87.5)         7 (87.5)         0 (0.0)         8 (100.0)           13 (12.4)         2 (15.4)         11 (84.6)         2 (15.4)         11 (84.6)         2 (15.4)         11 (84.6)           44 (41.9)         10 (22.7)         34 (77.3)         7 (15.9)         7 (16.9)         3 (16.6)         2 (15.4)         11 (84.6)           777 (74.0)         12 (15.6)         66 (84.4)         0.057         6 (7.8)         71 (92.2)         3 (3.9)         74 (96.1)           27 (26.0)         9 (33.3)         18 (66.7)         18 (66.7)         7 (82.0)         7 (18.6)         3 (3.9)         74 (96.1)           20 (19.0)         10 (50.0)         10 (50.0)         10 (50.0)         8 (40.0)         12 (60.0)         5 (25.0)         15 (75.0)           5 (4.8)         2 (4.8)         2 (4.8)         0 (20.0)         2 (10.0)         2 (10.0)         16 (19.0)         10 (13.3)         6 (18.0)         0 (0.0)         5 (10.0)           5 (4.8)         2 (4.8)         2 (4.8)         0 (20.0)	Higher education	20 (19.4)	5 (25.0)	15 (75.0)		5 (25.0)	15 (75.0)		2 (10.0)	18 (90.0)	
week         5 (4.8)         1 (20.0)         4 (80.0)         0.931         1 (20.0)         4 (80.0)         0.937         1 (20.0)         4 (80.0)           9 (7.6)         2 (25.0)         6 (75.0)         1 (12.5)         7 (87.5)         7 (87.5)         0 (0.0)         8 (100.0)           9 (7.6)         2 (25.0)         6 (75.0)         1 (14.6)         7 (15.9)         37 (84.1)         2 (15.4)         11 (84.6)           4 (41.9)         1 (22.7)         24 (77.3)         7 (15.9)         37 (84.1)         2 (15.4)         11 (84.6)           7 (74.0)         1 2 (15.6)         66 (84.4)         0.057         6 (7.8)         7 (162.2)         0.003         3 (8.6)         32 (91.4)           7 (74.0)         1 2 (15.6)         66 (84.4)         0.057         6 (7.8)         7 (162.2)         0.003         3 (8.6)         32 (91.4)           86 (81.0)         1 1 (12.9)         7 (87.1)         18 (66.7)         18 (66.7)         9 (33.3)         7 (88.7)         18 (80.1)         16 (15.0)         16 (15.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (10.0)         17 (1	Contact with GP										
Belos         13 (12.4)         2 (25.0)         6 (75.0)         1 (12.5)         7 (87.5)         7 (87.5)         7 (87.5)         7 (87.5)         7 (87.5)         7 (87.5)         7 (15.4)         11 (84.6)         8 (100.0)         8 (100.0)           13 (12.4)         10 (22.7)         34 (77.3)         7 (15.9)         7 (15.9)         37 (84.1)         2 (45.6)         11 (84.6)           35 (33.3)         6 (17.1)         29 (82.9)         4 (11.4)         31 (88.6)         2 (45.6)         4 (96.5)           77 (74.0)         12 (15.6)         65 (84.4)         0.057         6 (7.8)         7 (192.2)         0.003         3 (3.9)         7 (96.1)           27 (26.0)         9 (33.3)         18 (66.7)         7 (86.7)         7 (86.7)         18 (66.7)         9 (33.3)         7 (194.5)         7 (194.5)           86 (81.0)         11 (12.9)         7 (87.1)         0.001         7 (86.7)         8 (40.0)         12 (60.0)         15 (16.7)         16 (16.7)         16 (16.7)         10 (13.3)         65 (86.7)         4 (13.3)         17 (94.7)           100 (95.2)         19 (19.0)         19 (19.0)         10 (19.0)         10 (19.0)         10 (19.0)         11 (10.10)         11 (10.10)         11 (10.10)         11 (10.10)         11 (10	More than once a week	5 (4.8)	1 (20.0)	4 (80.0)	0.931	1 (20.0)	4 (80.0)	0.937	1 (20.0)	4 (80.0)	0.319
996Ks       13 (12.4)       2 (15.4)       11 (84.6)       2 (15.4)       11 (84.6)       2 (15.4)       11 (84.6)       <	Once a week	8 (7.6)	2 (25.0)	(0.52.0)		1 (12.5)	7 (87.5)		0 (0.0)	8 (100.0)	
44 (41.9)       10 (22.7)       34 (77.3)       7 (15.9)       37 (84.1)       2 (4.5)       42 (95.5)         35 (33.3)       6 (17.1)       29 (82.9)       4 (11.4)       31 (88.6)       31 (88.6)       3 (8.6)       32 (91.4)         77 (74.0)       12 (15.6)       65 (84.4)       0.057       6 (7.8)       71 (92.2)       0.003       3 (3.9)       74 (96.1)         27 (26.0)       9 (33.3)       18 (66.7)       7 (82.7)       78 (91.8)       0.001       3 (3.9)       74 (96.1)         86 (81.0)       10 (50.0)       10 (50.0)       10 (50.0)       10 (50.0)       10 (50.0)       10 (50.0)       10 (50.0)       10 (13.3)       65 (86.7)       26 (86.7)       10 (13.3)       66 (86.7)       10 (13.3)       66 (86.7)       10 (10.0)	Once every two weeks	13 (12.4)	2 (15.4)	11 (84.6)		2 (15.4)	11 (84.6)		2 (15.4)	11 (84.6)	
35 (33.3)       6 (17.1)       29 (82.9)       4 (11.4)       31 (88.6)       31 (88.6)       3 (8.6)       3 (8.6)       32 (91.4)         77 (74.0)       12 (15.6)       65 (84.4) <b>0.057</b> 6 (7.8)       7 (192.2) <b>0.003</b> 3 (3.9)       7 (4.61.1)         27 (26.0)       9 (33.3)       18 (66.7)       18 (66.7)       7 (8.2)       78 (91.8) <b>0.001</b> 3 (3.5)       22 (81.5)         85 (81.0)       11 (12.9)       74 (87.1) <b>0.001</b> 7 (8.2)       78 (91.8) <b>0.001</b> 3 (3.5)       82 (96.5)         20 (19.0)       10 (50.0)       10 (50.0)       10 (50.0)       20 (33.3)       66 (86.7)       5 (25.0)       15 (75.0)         30 (28.6)       8 (26.7)       22 (73.3)       0.291       5 (16.7)       25 (83.3)       0.759       4 (13.3)       26 (86.7)         5 (4.8)       2 (40.0)       3 (60.0)       0.261       1 (20.0)       4 (80.0)       0.545       0 (0.0)       5 (100.0)         100 (95.2)       19 (19.0)       81 (81.0)       14 (14.0)       86 (86.0)       9 (32.0)       9 (32.0)	Once a month	44 (41.9)	10 (22.7)	34 (77.3)		7 (15.9)	37 (84.1)		2 (4.5)	42 (95.5)	
77 (74.0)         12 (15.6)         65 (84.4)         0.057         6 (7.8)         71 (92.2)         0.003         3 (3.9)         74 (96.1)           27 (26.0)         9 (33.3)         18 (66.7)         0.001         7 (8.2)         78 (91.8)         0.001         3 (3.5)         22 (81.5)           85 (81.0)         11 (12.9)         74 (87.1)         0.001         7 (8.2)         78 (91.8)         0.001         3 (3.5)         82 (96.5)           20 (19.0)         10 (50.0)         10 (50.0)         10 (50.0)         20 (73.3)         0.291         5 (16.7)         25 (83.3)         0.759         4 (13.3)         26 (86.7)           5 (4.8)         2 (40.0)         3 (60.0)         0.261         1 (20.0)         4 (80.0)         0.545         0 (0.0)         5 (100.0)           100 (95.2)         19 (19.0)         81 (81.0)         14 (14.0)         86 (86.0)         0.545         0 (0.0)         9 (10.0)         9 (10.0)	Less (or no GP)	35 (33.3)	6 (17.1)	29 (82.9)		4 (11.4)	31 (88.6)		3 (8.6)	32 (91.4)	
77 (74.0)         12 (15.6)         65 (84.4)         0.057         6 (7.8)         71 (92.2)         0.003         3 (3.9)         74 (96.1)           27 (26.0)         9 (33.3)         18 (66.7)         18 (66.7)         18 (66.7)         9 (33.3)         74 (96.1)         74 (13.3)         74 (19.2)	Treatment goal										
27 (26.0)       9 (33.3)       18 (66.7)       18 (66.7)       18 (66.7)       18 (66.7)       18 (66.7)       18 (66.7)       20 (33.3)       5 (18.5)       22 (81.5)       22 (81.5)         85 (81.0)       11 (12.9)       74 (87.1)       74 (87.1)       10 (50.0)       10 (50.0)       10 (50.0)       12 (60.0)       5 (25.0)       15 (75.0)         20 (19.0)       10 (50.0)       10 (50.0)       10 (50.0)       22 (73.3)       0.291       5 (16.7)       25 (83.3)       0.759       4 (13.3)       26 (86.7)         75 (74.1)       13 (17.3)       62 (82.7)       10 (13.3)       65 (86.7)       4 (5.3)       71 (94.7)         5 (4.8)       2 (40.0)       3 (60.0)       0.261       1 (20.0)       4 (80.0)       0.545       0 (0.0)       5 (100.0)         100 (95.2)       19 (19.0)       81 (81.0)       14 (14.0)       86 (86.0)       95 (86.0)       92 (92.0)	Life prolongation	77 (74.0)	12 (15.6)	65 (84.4)	0.057	6 (7.8)	71 (92.2)	0.003	3 (3.9)	74 (96.1)	0.027
85 (81.0)       11 (12.9)       74 (87.1)       0.001       7 (8.2)       78 (91.8)       0.001       3 (3.5)       82 (96.5)         20 (19.0)       10 (50.0)       10 (50.0)       10 (50.0)       10 (50.0)       12 (60.0)       5 (25.0)       15 (75.0)         30 (28.6)       8 (26.7)       22 (73.3)       0.291       5 (16.7)       25 (83.3)       0.759       4 (13.3)       26 (86.7)         75 (74.1)       13 (17.3)       62 (82.7)       10 (13.3)       65 (86.7)       4 (5.3)       71 (94.7)         5 (4.8)       2 (40.0)       3 (60.0)       0.261       1 (20.0)       4 (80.0)       0.545       0 (0.0)       5 (100.0)         100 (95.2)       19 (19.0)       81 (81.0)       14 (14.0)       86 (86.0)       8 (80.0)       92 (92.0)	Palliation	27 (26.0)	9 (33.3)	18 (66.7)		18 (66.7)	9 (33.3)		5 (18.5)	22 (81.5)	
85 (81.0)       11 (12.9)       74 (87.1)       0.001       7 (8.2)       78 (91.8)       0.001       3 (3.5)       82 (96.5)         20 (19.0)       10 (50.0)       10 (50.0)       10 (50.0)       8 (40.0)       12 (60.0)       5 (25.0)       15 (75.0)         30 (28.6)       8 (26.7)       22 (73.3)       0.291       5 (16.7)       25 (83.3)       0.759       4 (13.3)       26 (86.7)         75 (74.1)       13 (17.3)       62 (82.7)       10 (13.3)       65 (86.7)       4 (6.3)       71 (94.7)         5 (4.8)       2 (40.0)       3 (60.0)       0.261       1 (20.0)       4 (80.0)       0.545       0 (0.0)       5 (100.0)         100 (95.2)       19 (19.0)       81 (81.0)       14 (14.0)       86 (86.0)       8 (8.0)       92 (92.0)	Chemotherapy										
20 (19.0)       10 (50.0)       10 (50.0)       8 (40.0)       12 (60.0)       5 (25.0)       15 (75.0)         30 (28.6)       8 (26.7)       22 (73.3)       0.291       5 (16.7)       25 (83.3)       0.759       4 (13.3)       26 (86.7)         75 (74.1)       13 (17.3)       62 (82.7)       10 (13.3)       65 (86.7)       4 (5.3)       71 (94.7)         5 (4.8)       2 (40.0)       3 (60.0)       0.261       1 (20.0)       4 (80.0)       0.545       0 (0.0)       5 (100.0)         100 (95.2)       19 (19.0)       81 (81.0)       14 (14.0)       86 (86.0)       8 (80.0)       92 (92.0)	Yes	85 (81.0)	11 (12.9)	74 (87.1)	0.001	7 (8.2)	78 (91.8)	0.001	3 (3.5)	82 (96.5)	9000
30 (28.6) 8 (26.7) 22 (73.3) 0.291 5 (16.7) 25 (83.3) 0.759 4 (13.3) 26 (86.7) 75 (74.1) 13 (17.3) 62 (82.7) 10 (13.3) 65 (86.7) 4 (80.0) 5 (100.0) 5 (100.0) 100 (95.2) 19 (19.0) 81 (81.0) 14 (14.0) 86 (86.0) 8 (80.0) 92 (92.0)	No	20 (19.0)	10 (50.0)	10 (50.0)		8 (40.0)	12 (60.0)		5 (25.0)	15 (75.0)	
30 (28.6)       8 (26.7)       22 (73.3)       0.291       5 (16.7)       25 (83.3)       0.759       4 (13.3)       26 (86.7)         75 (74.1)       13 (17.3)       62 (82.7)       10 (13.3)       65 (86.7)       4 (5.3)       71 (94.7)         5 (4.8)       2 (40.0)       3 (60.0)       0.261       1 (20.0)       4 (80.0)       0.545       0 (0.0)       5 (100.0)         100 (95.2)       19 (19.0)       81 (81.0)       14 (14.0)       86 (86.0)       8 (8.0)       92 (92.0)	Radiotherapy										
75 (74.1)       13 (17.3)       62 (82.7)       10 (13.3)       65 (86.7)       4 (5.3)       71 (94.7)         5 (4.8)       2 (40.0)       3 (60.0)       0.261       1 (20.0)       4 (80.0)       0.545       0 (0.0)       5 (100.0)         100 (95.2)       19 (19.0)       81 (81.0)       14 (14.0)       86 (86.0)       8 (8.0)       92 (92.0)	Yes	30 (28.6)	8 (26.7)	22 (73.3)	0.291	5 (16.7)	25 (83.3)	0.759	4 (13.3)	26 (86.7)	0.221
5 (4.8) 2 (40.0) 3 (60.0) 0.261 1 (20.0) 4 (80.0) 0.545 0 (0.0) 5 (100.0) 100 (95.2) 19 (19.0) 81 (81.0) 14 (14.0) 86 (86.0) 8 (80.0) 92 (92.0)	No	75 (74.1)	13 (17.3)	62 (82.7)		10 (13.3)	(298) (29		4 (5.3)	71 (94.7)	
5 (4.8) 2 (40.0) 3 (60.0) 0.261 1 (20.0) 4 (80.0) 0.545 0 (0.0) 5 (100.0) 100 (95.2) 19 (19.0) 81 (81.0) 14 (14.0) 86 (86.0) 86 (8.0) 92 (92.0)	Experimental therapy										
100 (95.2) 19 (19.0) 81 (81.0) 14 (14.0) 86 (86.0) 8 (80.0)	Yes	5 (4.8)	2 (40.0)	3 (60.0)	0.261	1 (20.0)	4 (80.0)	0.545	0.0) 0	5 (100.0)	1.000
	No	100 (95.2)	19 (19.0)	81 (81.0)		14 (14.0)	86 (86.0)		8 (8.0)	92 (92.0)	

K. PARDON ET AL. LUNG CANCER

Management   Man	TABLE 1 Continued										
S   2   9   2   665 7   1   633 9   0   10   1   1   1   1   1   1   1		All patients	Patients w	ho had euthana with those who	sia wish, o did not	Patients who request comp	had an explicit a vared with those	nd repeated who did not	Patients w compared	ho received euth with those who	anasia, did not
S   S   S   S   S   S   S   S   S   S			Wish	No wish	p-value#	Request	No request	p-value#	Euthanasia	No euthanasia	p-value#
3 (2.9)         2 (66.7)         1 (53.3)         0.101         1 (33.3)         2 (66.7)         1 (53.3)         2 (66.7)         1 (53.3)         2 (66.7)         2 (66.7)         7 (13.7)         4 (18.6)         2 (66.7)         2 (66.7)         7 (13.7)         4 (18.6)         2 (66.7)         4 (18.2)         7 (18.6)         7 (18.6)         4 (74.4)         4 (74.4)         4 (78.2)         2 (66.7)         4 (78.2)         2 (66.7)         4 (18.2)         4 (78.2)         4 (78.4)         4 (78.2)         2 (66.7)         4 (78.2)         4 (78.2)         2 (66.7)         4 (78.2)         4 (78.2)         2 (66.7)         4 (78.2)         4 (78.2)         4 (78.2)         4 (78.2)         2 (66.7)         4 (78.2)         4 (78.2)         4 (78.2)         4 (78.2)         4 (78.2)         2 (66.7)         4 (78.2) <th< td=""><td>Surgery</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Surgery										
(102 (97.1)         (19 (18 0))         (18 (18 0))         (14 (13.7))         (14 (18.0))	Yes	3 (2.9)	2 (66.7)	1 (33.3)	0.101	1 (33.3)	2 (66.7)	0.373	1 (33.3)	2 (66.7)	0.213
51 (48.6)         7 (13.7)         44 (66.3)         0.146         6 (11.8)         45 (82.2)         0.581         4 (7.4)         47 (92.2)           54 (51.4)         14 (25.9)         40 (4.1)         9 (16.7)         45 (83.3)         0.129         2 (4.2)         46 (95.8)           48 (45.7)         7 (14.6)         41 (85.4)         0.475         4 (8.3)         44 (91.7)         0.129         2 (4.2)         46 (95.8)           37 (35.2)         8 (21.6)         29 (78.4)         0.475         4 (8.3)         10 (66.7)         1 (27.7)         36 (92.8)           15 (14.3)         5 (33.3)         10 (66.7)         1 (66.7)         1 (66.7)         1 (27.0)         4 (9.6)           1 (1.0)         1 (25.0)         3 (75.0)         1 (25.0)         1 (25.0)         1 (25.0)         1 (25.0)           1 (1.0)         1 (100.0)         0 (0.0)         1 (100.0)         0 (0.0)         1 (100.0)         1 (25.0)         1 (25.0)           2 (2.1)         1 (100.0)         0 (0.0)         1 (100.0)         0 (0.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)	O Z	102 (97.1)	19 (18.6)	83 (81.4)		14 (13.7)	88 (86.3)		(6.9) 2	95 (93.1)	
51 (48.6)         7 (13.7)         44 (86.3)         0.146         6 (11.8)         45 (88.2)         0.581         4 (7.4)         47 (92.2)           54 (51.4)         14 (55.9)         40 (47.1)         9 (16.7)         45 (85.3)         4 (7.8)         4 (7.8)         4 (7.8)         5 (92.6)           34 (45.7)         7 (14.6)         41 (65.4)         0.475         4 (8.3)         4 (91.7)         0.129         2 (4.2)         4 (65.8)           3 (35.2)         8 (21.6)         29 (78.4)         0.475         1 (25.0)         1 (27.7)         36 (92.8)           1 (14.3)         1 (25.0)         3 (75.0)         1 (25.0)         1 (25.0)         1 (25.0)         3 (75.0)           1 (11.0)         0 (0.0)         1 (100.0)         0 (0.0)         1 (100.0) <td>Treating hospital</td> <td></td>	Treating hospital										
4 (45.4)         14 (25.9)         40 (74.1)         9 (16.7)         45 (83.3)         4 (78.3)         4 (78.3)         4 (85.4)         9 (16.7)         46 (83.3)         4 (85.4)         4 (85.8)	University	51 (48.6)	7 (13.7)	44 (86.3)	0.146	6 (11.8)	45 (88.2)	0.581	4 (7.4)	47 (92.2)	1.000
48 (45.7)         7 (14.6)         41 (65.4)         0.475         4 (8.3)         44 (91.7)         0.129         2 (4.2)         46 (95.8)           37 (35.2)         8 (21.6)         29 (78.4)         6 (13.5)         3 (1	General	54 (51.4)	14 (25.9)	40 (74.1)		9 (16.7)	45 (83.3)		4 (7.8)	50 (92.6)	
48 (45.7)         7 (14.6)         41 (65.4)         0.475         4 (8.3)         44 (91.7)         0.129         2 (4.2)         46 (95.6)           37 (35.2)         8 (21.6)         29 (78.4)         6 (33.3)         10 (66.7)         5 (33.3)         10 (66.7)         3 (75.0)         1 (27.0)         36 (97.3)           15 (14.3)         5 (33.3)         10 (66.7)         1 (25.0)         3 (75.0)         1 (125.0)         3 (75.0)         1 (173.3)           4 (3.8)         1 (25.0)         3 (75.0)         1 (125.0)         1 (105.0)         1 (105.0)         1 (105.0)         1 (105.0)         1 (105.0)           2 (2.1)         0 (0.0)         2 (100.0)         0 (0.0)         2 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         1 (100.0)         2 (100.0	Comorbidity <sup>+</sup>										
37 (35.2)         8 (21.6)         29 (78.4)         5 (13.5)         2 (66.5)         1 (12.7)         36 (97.3)           15 (33.3)         10 (66.7)         5 (33.3)         10 (66.7)         4 (26.7)         1 (175.0)         3 (75.0)           4 (3.8)         1 (25.0)         3 (75.0)         1 (25.0)         3 (75.0)         1 (170.0)         1 (170.0)           1 (1.10)         0 (0.0)         1 (100.0)         0 (0.0)         0 (0.0)         0 (0.0)         1 (100.0)         1 (100.0)           2 (2.1)         0 (0.0)         2 (100.0)         1 (100.0)         2 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)           2 (2.1)         0 (0.0)         2 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)           2 (2.1)         2 (10.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)           2 (2.1)         2 (10.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)         1 (100.0)	0 (No comorbidity)	48 (45.7)	7 (14.6)	41 (85.4)	0.475	4 (8.3)	44 (91.7)	0.129	2 (4.2)	46 (95.8)	0.020
15 (14.3)         5 (33.3)         10 (66.7)         5 (33.3)         10 (66.7)         4 (26.7)         11 (73.0)           4 (3.8)         1 (25.0)         3 (75.0)         1 (25.0)         3 (75.0)         1 (25.0)         3 (75.0)         1 (100.0)	-	37 (35.2)	8 (21.6)	29 (78.4)		5 (13.5)	32 (86.5)		1 (2.7)	36 (97.3)	
4 (3.8)         1 (25.0)         3 (75.0)         1 (25.0)         3 (75.0)         1 (25.0)         3 (75.0)           1 (1.0)         0 (0.0)         1 (100.0)         0 (0.0)         1 (100.0)         0 (0.0)         1 (100.0)         1 (100.0)           2 (2.1)         0 (0.0)         2 (100.	2	15 (14.3)	5 (33.3)	10 (66.7)		5 (33.3)	10 (66.7)		4 (26.7)	11 (73.3)	
1 (1.0)         0 (0.0)         1 (100.0)         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0)         1 (100.0)<	က	4 (3.8)	1 (25.0)	3 (75.0)		1 (25.0)	3 (75.0)		1 (25.0)	3 (75.0)	
0 (0.0)         0 (0.0) <t< td=""><td>4</td><td>1 (1.0)</td><td>0.0) 0</td><td>1 (100.0)</td><td></td><td>0.0) 0</td><td>1 (100.0)</td><td></td><td>0.0) 0</td><td>1 (100.0)</td><td></td></t<>	4	1 (1.0)	0.0) 0	1 (100.0)		0.0) 0	1 (100.0)		0.0) 0	1 (100.0)	
0 (0.0)         0 (0.0) <t< td=""><td>Characteristics near or at death</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Characteristics near or at death										
0 (0.0)         0 (0.0) <t< td=""><td>(source: specialist or GP<sup>§</sup>)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	(source: specialist or GP <sup>§</sup> )										
0 (0.0)         0 (0.0) <t< td=""><td>Performance status in last week before death 14</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Performance status in last week before death 14										
2 (2.1)         0 (0.0)         2 (100.0)         0 (0.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         2 (100.0)         4 (80.0)         2 (100.0)         4 (80.0)         2 (100.0)         4 (80.0)         2 (100.0)         4 (80.0)         1 (100.0)         4 (80.0)         1 (100.0)         4 (80.0)         1 (100.0)         4 (80.0)	0	0.0) 0	0.0) 0	0.0) 0	0.329	0.0) 0	0.0) 0	0.831	0.0) 0	0.0) 0	0.566
5 (5.2)         2 (40.0)         3 (60.0)         1 (20.0)         4 (80.0)         1 (20.0)         4 (80.0)	-	2 (2.1)	0.0) 0	2 (100.0)		0.0) 0	2 (100.0)		0.0) 0	2 (100.0)	
20 (20.6)         2 (10.0)         18 (90.0)         2 (10.0)         18 (90.0)         1 (15.7)         59 (84.3)         1 (5.0)         19 (95.0)           70 (72.2)         15 (21.4)         55 (78.6)         4.0 <b>0.021</b> 7.0         50 (84.3)         6 (8.6)         64 (91.4)           5.0         8.0         4.0 <b>0.021</b> 7.0         5.0         0.110         10.0         4.0           7.8 ± 2.1         8.2 ± 2.1         7.7 ± 2.1         0.219         8.5 ± 1.4         7.6 ± 2.2         0.180         9 (12.3)         64 (87.7)         0.498         7 (9.6)         66 (90.4)           73 (70.9)         11 (15.1)         62 (84.9)         0.180         9 (12.3)         64 (87.7)         0.498         7 (9.6)         66 (90.4)           15 (14.6)         5 (33.3)         10 (66.7)         3 (20.0)         12 (80.0)         1 (6.7)         14 (93.3)           15 (14.6)         4 (26.6)         11 (73.3)         3 (20.0)         12 (80.0)         0 (0.0)         15 (10.0)           94 (89.5)         19 (20.2)         75 (79.8)         1.000         15 (16.0)         79 (84.0)         0 (0.0)         11 (100.0)         11 (100.0)	Ø	5 (5.2)	2 (40.0)	3 (60.0)		1 (20.0)	4 (80.0)		1 (20.0)	4 (80.0)	
70 (72.2)         15 (21.4)         55 (78.6)         11 (15.7)         59 (84.3)         6 (8.6)         64 (91.4)           5.0         8.0         4.0         0.021         7.0         5.0         0.110         10.0         4.0           7.8±2.1         8.2±2.1         7.7±2.1         0.219         8.5±1.4         7.6±2.2         0.182         8.7±1.2         7.7±2.2           73 (70.9)         11 (15.1)         62 (84.9)         0.180         9 (12.3)         64 (87.7)         0.498         7 (9.6)         66 (90.4)           15 (14.6)         5 (33.3)         10 (66.7)         3 (20.0)         12 (80.0)         1 (6.7)         14 (93.3)           15 (14.6)         4 (26.6)         11 (73.3)         3 (20.0)         12 (80.0)         16 (0.0)         15 (100.0)           94 (89.5)         19 (20.2)         75 (79.8)         1.000         15 (16.0)         79 (84.0)         0 (0.0)         11 (100.0)           11 (10.5)         2 (18.2)         9 (81.8)         0 (0.0)         11 (100.0)         0 (0.0)         11 (100.0)	8	20 (20.6)	2 (10.0)	18 (90.0)		2 (10.0)	18 (90.0)		1 (5.0)	19 (95.0)	
5.0         8.0         4.0         0.021         7.0         5.0         0.110         10.0         4.0           7.8 ± 2.1         8.2 ± 2.1         7.7 ± 2.1         0.219         8.5 ± 1.4         7.6 ± 2.2         0.182         8.7 ± 1.2         7.7 ± 2.2           73 (70.9)         11 (15.1)         62 (84.9)         0.180         9 (12.3)         64 (87.7)         0.498         7 (9.6)         66 (90.4)           15 (14.6)         5 (33.3)         10 (66.7)         3 (20.0)         12 (80.0)         1 (6.7)         14 (93.3)           15 (14.6)         4 (26.6)         11 (73.3)         3 (20.0)         12 (80.0)         0 (0.0)         15 (100.0)           94 (89.5)         19 (20.2)         75 (79.8)         1.000         15 (16.0)         79 (84.0)         0 (35.8)         8 (8.5)         86 (91.5)           11 (10.5)         2 (18.2)         9 (81.8)         0 (0.0)         11 (100.0)         0 (0.0)         11 (100.0)         11 (100.0)         11 (100.0)	4	70 (72.2)	15 (21.4)	55 (78.6)		11 (15.7)	59 (84.3)		(8.6)	64 (91.4)	
7.8±2.1         8.2±2.1         7.7±2.1         0.219         8.5±1.4         7.6±2.2         0.182         8.7±1.2         7.7±2.2           73 (70.9)         11 (15.1)         62 (84.9)         0.180         9 (12.3)         64 (87.7)         0.498         7 (9.6)         66 (90.4)           15 (14.6)         5 (33.3)         10 (66.7)         3 (20.0)         12 (80.0)         1 (6.7)         14 (93.3)           15 (14.6)         4 (26.6)         11 (73.3)         3 (20.0)         12 (80.0)         0 (0.0)         15 (100.0)           94 (89.5)         19 (20.2)         75 (79.8)         1.000         15 (16.0)         79 (84.0)         0 (358         8 (8.5)         86 (91.5)           11 (10.5)         2 (18.2)         9 (81.8)         0 (0.0)         11 (100.0)         0 (0.0)         11 (100.0)	Median survival time in months after inclusion	5.0	8.0	4.0	0.021	7.0	5.0	0.110	10.0	4.0	0.003
73 (70.9)       11 (15.1)       62 (84.9)       0.180       9 (12.3)       64 (87.7)       0.498       7 (9.6)       66 (90.4)         15 (14.6)       5 (33.3)       10 (66.7)       3 (20.0)       12 (80.0)       12 (80.0)       1 (6.7)       14 (93.3)         15 (14.6)       4 (26.6)       11 (73.3)       3 (20.0)       12 (80.0)       12 (80.0)       15 (100.0)         94 (89.5)       19 (20.2)       75 (79.8)       1.000       15 (16.0)       79 (84.0)       0.358       8 (8.5)       86 (91.5)         11 (10.5)       2 (18.2)       9 (81.8)       0 (0.0)       11 (100.0)       0 (0.0)       11 (100.0)	Good death scores from 0 to 10 <sup>¶</sup>	7.8 ± 2.1	8.2±2.1	$7.7 \pm 2.1$	0.219	8.5±1.4	7.6±2.2	0.182	8.7±1.2	7.7±2.2	0.225
73 (70.9)         11 (15.1)         62 (84.9)         0.180         9 (12.3)         64 (87.7)         0.498         7 (9.6)         66 (90.4)           15 (14.6)         5 (33.3)         10 (66.7)         3 (20.0)         12 (80.0)         1 (6.7)         14 (93.3)           15 (14.6)         4 (26.6)         11 (73.3)         3 (20.0)         12 (80.0)         0 (0.0)         15 (100.0)           94 (89.5)         19 (20.2)         75 (79.8)         1.000         15 (16.0)         79 (84.0)         0.358         8 (8.5)         86 (91.5)           11 (10.5)         2 (18.2)         9 (81.8)         0 (0.0)         11 (100.0)         0 (0.0)         11 (100.0)	Setting where patient died										
15 (14.6)     5 (33.3)     10 (66.7)     3 (20.0)     12 (80.0)     1 (6.7)     14 (93.3)       15 (14.6)     4 (26.6)     11 (73.3)     3 (20.0)     12 (80.0)     0 (0.0)     15 (100.0)       94 (89.5)     19 (20.2)     75 (79.8)     1.000     15 (16.0)     79 (84.0)     0.358     8 (8.5)     86 (91.5)       11 (10.5)     2 (18.2)     9 (81.8)     0 (0.0)     11 (100.0)     0 (0.0)     11 (100.0)	Specialist care	73 (70.9)	11 (15.1)	62 (84.9)	0.180	9 (12.3)	64 (87.7)	0.498	(9.6) 2	66 (90.4)	0.839
15 (14.6)     4 (26.6)     11 (73.3)     3 (20.0)     12 (80.0)     12 (80.0)     15 (100.0)     15 (100.0)       94 (89.5)     19 (20.2)     75 (79.8)     1.000     15 (16.0)     79 (84.0)     0.358     8 (8.5)     86 (91.5)       11 (10.5)     2 (18.2)     9 (81.8)     0 (0.0)     11 (100.0)     0 (0.0)     11 (100.0)     11 (100.0)	GP care	15 (14.6)	5 (33.3)	10 (66.7)		3 (20.0)	12 (80.0)		1 (6.7)	14 (93.3)	
94 (89.5) 19 (20.2) 75 (79.8) 1.000 15 (16.0) 79 (84.0) 0.358 8 (8.5) 86 (91.5) 11 (10.5) 2 (18.2) 9 (81.8) 0 (0.0) 11 (100.0) 0 (0.0)	Other (e.g. nursing home)	15 (14.6)	4 (26.6)	11 (73.3)		3 (20.0)	12 (80.0)		0.0) 0	15 (100.0)	
94 (89.5) 19 (20.2) 75 (79.8) 1.000 15 (16.0) 79 (84.0) 0.358 8 (8.5) 86 (91.5) (11 (10.5) 2 (18.2) 9 (81.8) 0 (0.0) 11 (100.0) 0 (0.0) 11 (100.0)	Sudden, unexpected death										
11 (10.5) 2 (18.2) 9 (81.8) 0 (0.0) 11 (100.0) 0 (0.0)	° N	94 (89.5)	19 (20.2)	75 (79.8)	1.000	15 (16.0)	79 (84.0)	0.358	8 (8.5)	86 (91.5)	0.596
	Yes	11 (10.5)	2 (18.2)	9 (81.8)		0.0) 0	11 (100.0)		0.0) 0	11 (100.0)	

n=2 for education, n=1 for treatment goal, n=8 for performance status in last week before death, n=8 for good death, n=2 for setting where patient died. \*: comorbidity according to Charlson Index. \*: according to the patient died or if the patient died in another setting according to the physician who had the most contact with the patient in the last month before death. \*!: performance status Data are presented as mean±sp or n (%), unless otherwise stated. \*: significance testing with Mann-Whitney U or Fisher's exact test. Bold values indicate significant p-values. \*! missing values: n=3 for having a partner, according to the Eastern Cooperative Oncology Group (ECOG), ranging from 0 = fully active to 4 = completely disabled.

EUROPEAN RESPIRATORY JOURNAL VOLUME 40 NUMBER 4 953




FIGURE 2. Euthanasia in advanced lung cancer patients, according to the treating specialist and/or general practitioner (GP) of the patient. When, if both were applicable, specialist and GP disagreed over presence of wish or explicit and repeated request, presence of wish or explicit and repeated request was entered in the flow chart. NSCLC: nonsmall cell lung cancer; ELD: end-of-life decisions with possible or certain life-shortening effects.

to shorten life in 2.9% of cases and with intent in 11.4%). In 41 (39.1%) patients, symptom alleviation was intensified but in most of these cases (32.4%) life-shortening was not an additional intention. In two (1.9%) patients lethal drugs were administered

TABLE 2

Frequency of end-of-life decisions in advanced lung cancer patients who died within 18 months after diagnosis of nonsmall cell lung cancer#

Patients n	105
All deaths preceded by at least one ELD	66 (62.9)
Withholding or withdrawing of potential	15 (14.3)
life-prolonging treatment	
Life-shortening not intended	3 (2.9)
Life-shortening intended	12 (11.4)
Intensifying alleviation of symptoms with	41 (39.1)
a potential life-shortening effect	
Life-shortening not intended	34 (32.4)
Life-shortening additionally intended	7 (6.7)
Physician assisted death	10 (9.5)
Euthanasia	8 (7.6)
Physician assisted suicide	0 (0.0)
Ending of life without patients explicit request	2 (1.9)

Data are presented as n (%), unless otherwise stated. ELD: end-of-life decisions with possible or certain life-shortening effects. #: according to the physician (general practitioner or specialist) in which setting the patient died or if the patient died in another setting according to the physician who had the most contact with the patient in the last month before death.

with the explicit intention to shorten the patient life without their explicit request.

Independently of whether or not the aforementioned ELDs had been made, a separate question was asked about the incidence of continuous deep sedation until death. This procedure was applied in 13 patients or 12.4% of cases (4.8% with artificial hydration and/or nutrition and 7.6% without).

# DISCUSSION

This is the first study on euthanasia and the incidence of other end-of-life decisions with possible or certain life-shortening effects in a sample of patients with advanced lung cancer (n=105). One-fifth of the studied advanced lung cancer patients who died within 18 months after diagnosis of fatal lung cancer had expressed a wish for euthanasia according to their GP and/or specialist. In three-quarters of these an explicit and repeated request was made and one-half of these effectively received euthanasia (7.6% of all patients). Patients whose treatment goal was exclusively palliative and those who did not receive chemotherapy at inclusion were more likely to express a wish for euthanasia, to make an explicit and repeated request for euthanasia and to receive euthanasia. ELDs other than euthanasia occurred in 55.3% of cases: intensified alleviation of pain and symptoms occurred in most cases (39.1%), followed by non-treatment decisions (14.3%) and ending of life without patient's explicit request (1.9%).

A strength of the study was that in contrast with nationwide death certificate studies, the assessment of ELDs was performed by questioning both the treating specialist and the GP, and immediately after the patient had died, thus avoiding K. PARDON ET AL. LUNG CANCER

recall bias [19]. In addition, this study provided data on the qualification of the wish for euthanasia and the care process preceding the performance of euthanasia. Limitations of the study were the relatively small sample size and the limited response rate of the GPs, who were, however, probably less involved in the care of lung cancer patients at the end of life. Another limitation was that this was a physician survey only. A more general remark concerns the generalisability of the study findings: the results of this Flemish study cannot be automatically extrapolated to other European countries that for instance have no law on euthanasia or that place a lower value on the principle of patient autonomy in medical decision making compared with other principles.

A substantial fraction (20%) of the studied advanced lung cancer patients who died within 18 months after diagnosis had expressed a wish for euthanasia and three-quarters of these patients had also explicitly and repeatedly requested euthanasia. This relationship between expressed wishes and making an explicit and repeated request in our sample is a novel finding. It shows that in most patients an expressed wish for euthanasia reflects determination, and not a reversible state of mind or a spurious reaction to a temporary condition.

Of those patients who had made an explicit and repeated request, around half actually received euthanasia. These percentages are somewhat higher than what was found in a Dutch physician survey of non-sudden cancer deaths in 2005 where 15% of the cancer patients made an explicit request of euthanasia (the repeated nature of the request was not specified), which were granted in one-third of the cases [20]. In both countries explicit requests for euthanasia were not necessarily honoured. In our study as well as in other Dutch studies the most frequent reasons given for this discrepancy were that the patient withdrew the request or died before the request was granted [21]. However, in our study we observed that in some cases the physician in whose setting the patient died was not aware of a wish, let alone a request because these were expressed to another treating physician. A possible explanation for this discrepancy between physicians was that the patient only told one physician about his euthanasia wish/request and not the other, e.g. because of the delicacy of the topic. Although less likely, it is also possible that the patient told both physicians but that one physician did not register the euthanasia wish/request or interpreted it otherwise, e.g. because of moral objections. Whatever the reasons for these discrepancies are, it is important that the patients tell all their treating physicians clearly what they want at the end of life and that there is an open and regular communication between the treating physicians.

The mere expression of a wish for euthanasia short of an explicit and repeated request did not result in euthanasia. This suggests that the physicians are aware of the stringent legal requirements of due consideration and reiteration of requests for euthanasia, that they comply with them and that they do not perform euthanasia out of these important safeguards [6]. It may also indicate that only determined patients, who are able to verbalise their wishes unambiguously and repeatedly, will have their requests granted.

Expressing a wish for euthanasia, making an explicit or repeated request for euthanasia or receiving euthanasia was independent of a patient's age, sex and education. There was an association with a palliative goal setting in the care plan at diagnosis of the advanced stage of the lung cancer. This may have different explanations. It is possible that these patients were more ill and therefore more inclined to discuss end-of-life issues including euthanasia. It is also likely that a life-prolonging therapeutic objective deflects concerns about the end of life. A related observation was that not receiving chemotherapy following the diagnosis of the advanced lung cancer was also strongly associated with a wish/request/performance of euthanasia. Another finding was that patients who survived longer were more inclined to have a euthanasia wish. This suggests that a long therapeutic relationship may facilitate communication on euthanasia.

Explanations for our finding of an association between an expressed wish for euthanasia and dying at home in the primary care setting can only be speculative and requires further research. One hypothesis is that patients having a preference for euthanasia also prefer to die at home and have more confidence in their GP for carrying out their requests.

Noteworthy is that the incidence of ELDs (including euthanasia) in advanced lung cancer patients is similar to that of all cancer patients in Flanders: at least one ELD was made in 62.9% and 64.2% of patients, respectively. The incidences of specific ELDs were also similar to the incidences in Belgian and Dutch cancer populations [22].

To conclude, several recommendations can be made. First, lung cancer physicians should prepare for patients who express a wish for euthanasia because these patients are likely to be determined. Secondly, physicians should be attentive for communication errors: especially in cases of transfer to other care settings where patients' euthanasia requests might not be picked up. Finally, it is important that physicians develop a good relationship with their patients and are open for discussions about palliative care in order to facilitate ELD discussions with their patients.

# **SUPPORT STATEMENT**

This study was funded by the Fund for Scientific Research in Flanders, Belgium (Project No. FWO/AL336), the Research Council of the Vrije Universiteit Brussel (Project No. HOA2 and OZR1218) and the AstraZeneca Foundation. The sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, and approval of the manuscript.

## STATEMENT OF INTEREST

A statement of interest for J.L. Bernheim can be found at www.erj. ersjournals.com/site/misc/statements.xhtml

# **ACKNOWLEDGEMENTS**

This EOLIC study on End-Of-Life Information and Communication was conducted in collaboration with a consortium of physicians who all recruited advanced lung cancer patients for inclusion in this study: D. Ommeslag (Hospital Sint-Lucas, Ghent, Belgium), R. Devogelaere (Hospital Damiaan, Oostende, Belgium), J. Van Meerbeeck (University Hospital of Ghent, Ghent, Belgium), J. Lamont (Hospital Maria Middelares, Ghent, Belgium), A. Lefebure (ZNA Sint Erasmus Hospital, Borgerhout, Belgium), L. Van Moorter (City Hospital Aalst, Aalst, Belgium), W. Elinck (Hospital Jan Palfijn, Ghent, Belgium), C. Van Schaardenburg (ZNA Jan Palfijn Hospital, Merksem, Belgium), A. Janssens (University Hospital of Antwerp, Edegem, Belgium), E. Potvin (Hospital Sint-Augustinus, Wilrijk, Belgium), A. Debrock (Hospital Sint-Augustinus,



EUROPEAN RESPIRATORY JOURNAL VOLUME 40 NUMBER 4 955

Wilrijk, Belgium), D. Verresen (Hospital Sint-Augustinus, Wilrijk, Belgium), E. De Droogh (ZNA Middelheim Hospital, Antwerp, Belgium), C. Pollefliet (University Hospital of Antwerp, Edegem, Belgium), K. Vermaelen (University Hospital of Ghent, Ghent, Belgium) and E. van Schoote (University Hospital of Ghent, Ghent, Belgium).

The following hospitals in Belgium participated in this study: ZNA Middelheim Hospital, Antwerp; University Hospital of Brussels, Brussels; University Hospital of Ghent, Ghent; Hospital Maria Middelares, Ghent; Hospital Jan Palfijn, Ghent; ZNA Sint Erasmus Hospital, Borgerhout; Hospital Sint-Lucas, Ghent; City Hospital Aalst, Aalst; ZNA Jan Palfijn Hospital, Merksem; Hospital Damiaan, Oostende; Hospital Sint-Augustinus, Wilrijk; University Hospital of Antwerp, Edegem; and Hospital Sint-Elisabeth, Turnhout.

We thank C. Pauwels-Delanghe (data manager for the EOLIC-study of the End-of-Life Care Research group of the Ghent University and Vrije Universiteit Brussel), E. Michiels (general practitioner and former researcher of the End-of-Life Care Research group of the Ghent University and Vrije Universiteit Brussel), J. Ruthven (English editor) and all the patients, caregivers and interviewers who have contributed to this work.

### **REFERENCES**

- 1 Deliens L, Mortier F, Bilsen J, et al. End-of-life decisions in medical practice in Flanders, Belgium: a nationwide survey. Lancet 2000; 356: 1806–1811.
- 2 Bilsen J, Cohen J, Chambaere K, et al. Medical end-of-life practices under the euthanasia law in Belgium. N Engl J Med 2009; 361: 1119–1121.
- **3** van der Heide A, Deliens L, Faisst K, et al. End-of-life decision-making in six European countries: descriptive study. *Lancet* 2003; 362: 345–350.
- **4** Emanuel EJ. Euthanasia and physician-assisted suicide: a review of the empirical data from the United States. *Arch Intern Med* 2002; 162: 142–152.
- **5** Kuhse H, Singer P, Baume P, *et al.* End-of-life decisions in Australian medical practice. *Med J Aust* 1997; 166: 191–196.
- **6** Wet betreffende euthanasie 28 mei 2002. Belgisch Staatsblad 22 juni 2002. [Law concerning euthanasia May 28, 2002. Belgian official collection of the Laws June 22, 2002] (in Dutch).
- 7 Wet toetsing levensbeëindiging op verzoek en hulp bij zelfdoding 1 april, 2002. [Termination of Life on Request and Assisted Suicide (Review Procedures) Act April 1, 2002] (in Dutch).
- 8 Loi du 16 mars 2009 sur l'euthanasie et l'assistance au suicide [Law of March 16, 2009 on euthanasia and assisted-suicide]. (in French).

**9** Bilsen J, Vander Stichele R, Broeckaert B, *et al.* Changes in medical end-of-life practices during the legalization process of euthanasia in Belgium. *Soc Sci Med* 2007; 65: 803–808.

- 10 van der Heide A, Onwuteaka-Philipsen BD, Rurup ML, et al. Endof-life practices in the Netherlands under the Euthanasia Act. N Engl J Med 2007; 356: 1957–1965.
- 11 Smith W, Khuri FR. The care of the lung cancer patient in the 21st century: a new age. *Semin Oncol* 2004; 31: 11–15.
- 12 Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology 2001; 10: 19–28.
- 13 Wet betreffende de patiëntenrechten 22 augustus 2002. Belgisch Staatsblad 26 september 2002 [Law concerning patient rights August 22, 2002. Belgian official collection of the Laws September 26, 2002] (in Dutch).
- 14 Cohen J, Marcoux I, Bilsen J, et al. European public acceptance of euthanasia: socio-demographic and cultural factors associated with the acceptance of euthanasia in 33 European countries. Soc Sci Med 2006; 63: 743–756.
- 15 Pardon K, Deschepper R, Vander Stichele R, et al. Preferences of advanced lung cancer patients for patient-centred information and decision-making: a prospective multicentre study in 13 hospitals in Belgium. Patient Educ Couns 2009; 77: 421–429.
- 16 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
- **17** Extermann M. Measuring comorbidity in older cancer patients. *Eur J Cancer* 2000; 36: 453–471.
- **18** Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
- **19** Chambaere K, Bilsen J, Cohen J, *et al.* A post-mortem survey on end-of-life decisions using a representative sample of death certificates in Flanders, Belgium: research protocol. *BMC Public Health* 2008; 8: 299.
- 20 Onwuteaka-Philipsen BD, Rurup ML, Pasman HR, et al. The last phase of life: who requests and who receives euthanasia or physician-assisted suicide? Med Care 2010; 48: 596–603.
- 21 Jansen-van der Weide MC, Onwuteaka-Philipsen BD, Van Der WG. Granted, undecided, withdrawn, and refused requests for euthanasia and physician-assisted suicide. *Arch Intern Med* 2005; 165: 1698–1704.
- **22** Chambaere K, Bilsen J, Cohen J, et al. Trends in medical end-of-life decision making in Flanders, Belgium 1998-2001-2007. *Med Decis Making* 2011; 31: 500–510.

956 VOLUME 40 NUMBER 4 EUROPEAN RESPIRATORY JOURNAL